175 related articles for article (PubMed ID: 30390146)
1. Targeting CTCFL/BORIS for the immunotherapy of cancer.
Loukinov D
Cancer Immunol Immunother; 2018 Dec; 67(12):1955-1965. PubMed ID: 30390146
[TBL] [Abstract][Full Text] [Related]
2. A Therapeutic Vaccine Targeting Rat BORIS (CTCFL) for the Treatment of Rat Breast Cancer Tumors.
Loukinov D; Anderson AL; Mkrtichyan M; Ghochikyan A; Rivero-Hinojosa S; Tucker J; Lobanenkov V; Agadjanyan MG; Nelson EL
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983050
[TBL] [Abstract][Full Text] [Related]
3. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
Alberti L; Losi L; Leyvraz S; Benhattar J
PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
[TBL] [Abstract][Full Text] [Related]
4. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
Hoivik EA; Kusonmano K; Halle MK; Berg A; Wik E; Werner HM; Petersen K; Oyan AM; Kalland KH; Krakstad C; Trovik J; Widschwendter M; Salvesen HB
Oncotarget; 2014 Feb; 5(4):1052-61. PubMed ID: 24658009
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of BORIS/CTCFL efficiently regulates cancer stemness and metastasis in MYCN amplified neuroblastoma cell line by modulating Wnt/β-catenin signaling pathway.
Garikapati KR; Patel N; Makani VKK; Cilamkoti P; Bhadra U; Bhadra MP
Biochem Biophys Res Commun; 2017 Feb; 484(1):93-99. PubMed ID: 28104398
[TBL] [Abstract][Full Text] [Related]
6. High expression of hTERT and stemness genes in BORIS/CTCFL positive cells isolated from embryonic cancer cells.
Alberti L; Renaud S; Losi L; Leyvraz S; Benhattar J
PLoS One; 2014; 9(10):e109921. PubMed ID: 25279549
[TBL] [Abstract][Full Text] [Related]
7. Widespread expression of BORIS/CTCFL in normal and cancer cells.
Jones TA; Ogunkolade BW; Szary J; Aarum J; Mumin MA; Patel S; Pieri CA; Sheer D
PLoS One; 2011; 6(7):e22399. PubMed ID: 21811597
[TBL] [Abstract][Full Text] [Related]
8. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.
Asano T; Hirohashi Y; Torigoe T; Mariya T; Horibe R; Kuroda T; Tabuchi Y; Saijo H; Yasuda K; Mizuuchi M; Takahashi A; Asanuma H; Hasegawa T; Saito T; Sato N
Oncotarget; 2016 Mar; 7(10):11223-37. PubMed ID: 26849232
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of BORIS/CTCFL leads to ROS-dependent cellular senescence and drug sensitivity in MYCN-amplified neuroblastoma.
Rao GK; Makani VKK; Mendonza JJ; Edathara PM; Patel N; Ramakrishna M; Cilamkoti P; Chiring Phukon J; Jose J; Bhadra U; Bhadra MP
FEBS J; 2022 May; 289(10):2915-2934. PubMed ID: 34854238
[TBL] [Abstract][Full Text] [Related]
10. Expression of the epigenetic factor BORIS (CTCFL) in the human genome.
de Necochea-Campion R; Ghochikyan A; Josephs SF; Zacharias S; Woods E; Karimi-Busheri F; Alexandrescu DT; Chen CS; Agadjanyan MG; Carrier E
J Transl Med; 2011 Dec; 9():213. PubMed ID: 22168535
[TBL] [Abstract][Full Text] [Related]
11. MAGEA1 inhibits the expression of BORIS via increased promoter methylation.
Zhao J; Wang Y; Liang Q; Xu Y; Sang J
J Cell Sci; 2019 Jan; 132(1):. PubMed ID: 30498011
[TBL] [Abstract][Full Text] [Related]
12. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy.
Horibe R; Hirohashi Y; Asano T; Mariya T; Suzuki T; Takaya A; Saijo H; Shionoya Y; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Watanabe K; Atsuyama E; Toji S; Hirano H; Hasegawa T; Takahashi H; Sato N; Torigoe T
PLoS One; 2017; 12(3):e0171460. PubMed ID: 28248963
[TBL] [Abstract][Full Text] [Related]
13. The combined action of CTCF and its testis-specific paralog BORIS is essential for spermatogenesis.
Rivero-Hinojosa S; Pugacheva EM; Kang S; Méndez-Catalá CF; Kovalchuk AL; Strunnikov AV; Loukinov D; Lee JT; Lobanenkov VV
Nat Commun; 2021 Jun; 12(1):3846. PubMed ID: 34158481
[TBL] [Abstract][Full Text] [Related]
14. BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas.
Hines WC; Bazarov AV; Mukhopadhyay R; Yaswen P
PLoS One; 2010 Mar; 5(3):e9738. PubMed ID: 20305816
[TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant.
Loukinov D; Ghochikyan A; Mkrtichyan M; Ichim TE; Lobanenkov VV; Cribbs DH; Agadjanyan MG
J Cell Biochem; 2006 Aug; 98(5):1037-43. PubMed ID: 16741971
[TBL] [Abstract][Full Text] [Related]
16. BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.
Link PA; Zhang W; Odunsi K; Karpf AR
Cancer Immun; 2013; 13():6. PubMed ID: 23390377
[TBL] [Abstract][Full Text] [Related]
17. BORIS/CTCFL epigenetically reprograms clustered CTCF binding sites into alternative transcriptional start sites.
Pugacheva EM; Bhatt DN; Rivero-Hinojosa S; Tajmul M; Fedida L; Price E; Ji Y; Loukinov D; Strunnikov AV; Ren B; Lobanenkov VV
Genome Biol; 2024 Jan; 25(1):40. PubMed ID: 38297316
[TBL] [Abstract][Full Text] [Related]
18. BORIS/CTCFL expression activates the TGFβ signaling cascade and induces Drp1 mediated mitochondrial fission in neuroblastoma.
Makani VKK; Mendonza JJ; Edathara PM; Yerramsetty S; Pal Bhadra M
Free Radic Biol Med; 2021 Nov; 176():62-72. PubMed ID: 34534628
[TBL] [Abstract][Full Text] [Related]
19.
Hillman JC; Pugacheva EM; Barger CJ; Sribenja S; Rosario S; Albahrani M; Truskinovsky AM; Stablewski A; Liu S; Loukinov DI; Zentner GE; Lobanenkov VV; Karpf AR; Higgins MJ
Mol Cancer Res; 2019 Oct; 17(10):2051-2062. PubMed ID: 31292201
[TBL] [Abstract][Full Text] [Related]
20. The structural complexity of the human BORIS gene in gametogenesis and cancer.
Pugacheva EM; Suzuki T; Pack SD; Kosaka-Suzuki N; Yoon J; Vostrov AA; Barsov E; Strunnikov AV; Morse HC; Loukinov D; Lobanenkov V
PLoS One; 2010 Nov; 5(11):e13872. PubMed ID: 21079786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
